Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-202-6 | CAS number: 1313-13-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
Oral
In accordance with Column 1 of REACH Annexes VIII, IX and X, repeated dose toxicity testing on the most appropriate route of administration shall be conducted having regard to the likely route of human exposure. For the registered substance, inhalation is deemed to be the most likely route of human exposure and therefore repeated dose toxicity testing via the oral route is not considered scientifically necessary.
To expand, the substance is used in industrial settings where ingestion is extremely unlikely. In the event of ingestion – acute exposure; the acute oral toxicity test prescribed in REACH Annex VIII resulted in an LD50 in excess of 2000 mg/kg bw. Moreover, airborne exposure is the most likely the work place. Furthermore, on animal welfare grounds, adaptation is appropriate in consideration of the extensive use of experimental animals that would be required.
Inhalation
MnO2 will be proposed for classification as STOT RE2- target organ brain, on the basis of the Roels et al (1992) study on workers exposed to the substance without any confounders. The route of exposure in the study was inhalation and the sub-clinical effects seen at the exposure concentrations in the study, are believed to indicate that significant toxicity could occur at moderate exposure levels. On the basis of this proposal it is considered that conducting animal testing would be both scientifically unjustified and unethical. Therefore in accordance with Annex XI, section 1.1 this test is not considered necessary.
Dermal
In accordance with Column 1 of REACH Annexes VIII, IX and X, repeated dose toxicity testing on the most appropriate route of administration shall be conducted having regard to the likely route of human exposure. For the registered substance, inhalation is deemed to be the most likely route of human exposure and therefore repeated dose toxicity testing via the dermal route is not considered scientifically necessary.
The physiochemical properties of MnO2 suggest it is unlikely to be absorbed through the skin. It has a poor water solubility and inorganic ions do not pass easily through the dermal barrier. In addition, MnO2 is not acutely toxic by the oral route and therefore it is highly unlikely that it would be toxic via the dermal route which in general absorbs chemicals to a much lesser degree than the gastrointestinal tract. Furthermore, on animal welfare grounds, adaptation is appropriate in consideration of the extensive use of experimental animals that would be required.
Justification for classification or non-classification
In accordance with the criteria for classification as defined in Annex I, Regulation (EC) No. 1272/2008, the substance is classified with respect to specific target organ toxicity following repeated exposure, and has the hazard phrase 'H373: May cause damage to the brain through prolonged or repeated exposure via inhalation'.
In accordance with the criteria for classification as defined in Annex VI, Directive 67/548/EEC (DSD), the substance is classified with respect to repeated dose toxicity and has the risk phrase 'R48/20 - Harmful: danger of serious damage to health by prolonged exposure through inhalation'.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
This website uses cookies to ensure you get the best experience on our websites.